Sturgeon K.M., Deng L., Bluethmann S.M. et al. A populationbased study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 2019;40(48):3889–97. DOI: 10.1093/eurheartj/ehz766.
DOI: 10.1093/eurheartj/ehz766
Armstrong G.T., Liu Q., Yasui Y. et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009;27(14):2328–38. DOI: 10.1200/JCO.2008.21.1425.
DOI: 10.1200/JCO.2008.21.1425
Plana J.C., Galderisi M., Barac A. et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014;15(10):1063–93. DOI: 10.1093/ehjci/jeu192.
DOI: 10.1093/ehjci/jeu192
Zamorano J.L., Lancellotti P., Rodriguez Muñoz D. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37(36):2768–801. DOI: 10.1093/eurheartj/ehw211.
DOI: 10.1093/eurheartj/ehw211
Armenian S.H., Hudson M.M., Mulder R.L. et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2015;16(3):e123–36. DOI: 10.1016/S1470-2045(14)70409-7.
DOI: 10.1016/S1470-2045(14)70409-7
Seidman A., Hudis C., Pierri M.K. et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20(5):1215–21. DOI: 10.1200/JCO.2002.20.5.1215.
DOI: 10.1200/JCO.2002.20.5.1215
Schwartz R.G., McKenzie W.B., Alexander J. et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987;82(6):1109–18. DOI: 10.1016/0002-9343(87)90212-9.
DOI: 10.1016/0002-9343(87)90212-9
Thavendiranathan P., Grant A.D., Negishi T. et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 2013;61(1):77–84. DOI: 10.1016/j.jacc.2012.09.035.
DOI: 10.1016/j.jacc.2012.09.035
Otterstad J.E., Froeland G., St John Sutton M., Holme I. Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. Eur Heart J 1997;18(3):507–13. DOI: 10.1093/oxfordjournals.eurheartj.a015273.
DOI: 10.1093/oxfordjournals.eurheartj.a015273
Armstrong G.T., Plana J.C., Zhang N. et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012;30(23):2876–84. DOI: 10.1200/JCO.2011.40.3584.
DOI: 10.1200/JCO.2011.40.3584
Bellenger N.G., Burgess M.I., Ray S.G. et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J 2000;21(16):1387–96. DOI: 10.1053/euhj.2000.2011.
DOI: 10.1053/euhj.2000.2011
Grothues F., Smith G.C., Moon J.C. et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 2002;90(1):29–34. DOI: 10.1016/s0002-9149(02)02381-0.
DOI: 10.1016/s0002-9149(02)02381-0
Suerken C.K., D’Agostino R.B. Jr., Jordan J.H. et al. Simultaneous left ventricular volume and strain changes during chemotherapy associate with 2-year postchemotherapy measures of left ventricular ejection fraction. J Am Heart Assoc 2020;9(2):e015400. DOI: 10.1161/JAHA.119.015400.
DOI: 10.1161/JAHA.119.015400
Negishi T., Thavendiranathan P., Negishi K., Marwick T.H. Rationale and design of the strain surveillance of chemotherapy for improving cardiovascular outcomes: the SUCCOUR trial. JACC Cardiovasc Imaging 2018;11(8):1098–105. DOI: 10.1016/j.jcmg.2018.03.019.
DOI: 10.1016/j.jcmg.2018.03.019
Steen H., Montenbruck M., Wuelfing P. et al. P3118CMR Fast-SENC intramyocardial LV & RV segmental strain detects cardiotoxicity during oncology treatment and impact of cardioprotection therapy before echocardiography. Eur Heart J 2019;40(Suppl_1);ehz745.0193. DOI: 10.1093/eurheartj/ehz745.0193.
DOI: 10.1093/eurheartj/ehz745.0193
Jolly M.P., Jordan J.H., Meléndez G.C. et al. Automated assessments of circumferential strain from cine CMR correlate with LVEF declines in cancer patients early after receipt of cardio-toxic chemotherapy. J Cardiovasc Magn Reson 2017;19(1):59. DOI: 10.1186/s12968-017-0373-3.
DOI: 10.1186/s12968-017-0373-3
Salem J.E., Manouchehri A., Moey M. et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 2018;19(12):1579–89. DOI: 10.1016/S1470-2045(18)30608-9.
DOI: 10.1016/S1470-2045(18)30608-9
Johnson D.B., Balko J.M., Compton M.L. et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375(18):1749–55. DOI: 10.1056/NEJMoa1609214.
DOI: 10.1056/NEJMoa1609214
Zhang L., Awadalla M., Mahmood S.S. et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J 2020;7;41(18):1733–43. DOI: 10.1093/eurheartj/ehaa051.
DOI: 10.1093/eurheartj/ehaa051
Скрябина Е.Н., Сафонова В.Н., Агарева Т.А. Редкий случай эндокардита Леффлера как проявление эозинофильного гранулематоза с полиангиитом. Саратовский научно-медицинский журнал 2017;13(4):823–8.
Allderdice C., Marcu C., Kabirdas D. Intracardiac thrombus in leukemia: role of cardiac magnetic resonance imaging in eosinophilic myocarditis. CASE (Phila) 2018 Jun;2(3):114–7. DOI: 10.1016/j.case.2017.12.003.
DOI: 10.1016/j.case.2017.12.003
Plácido R., Cunha Lopes B., Almeida A.G., Rochitte C.E. The role of cardiovascular magnetic resonance in takotsubo syndrome. J Cardiovasc Magn Reson 2016;18(1):68. DOI: 10.1186/s12968-016-0279-5.
DOI: 10.1186/s12968-016-0279-5
Engblom H., Xue H., Akil S. et al. Fully quantitative cardiovascular magnetic resonance myocardial perfusion ready for clinical use: a comparison between cardiovascular magnetic resonance imaging and positron emission tomography. J Cardiovasc Magn Reson 2017;19(1):78. DOI: 10.1186/s12968-017-0388-9..
DOI: 10.1186/s12968-017-0388-9
Chaosuwannakit N., DʼAgostino R. Jr., Hamilton C.A. et al. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol 2010;28(1):166–72. DOI: 10.1200/JCO.2009.23.8527.
DOI: 10.1200/JCO.2009.23.8527
Gertz M.A. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol 2016;91(9): 947–56.
Zhao L., Tian Z., Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis. BMC Cardiovasc Disord 2016;16:129. DOI: 10.1186/s12872-016-0311-6.
DOI: 10.1186/s12872-016-0311-6
Motwani M., Kidambi A., Herzog B.A. et al. MR imaging of cardiac tumors and masses: a review of methods and clinical applications. Radiology 2013;268(1):26–43. DOI: 10.1148/radiol.13121239.
DOI: 10.1148/radiol.13121239
Cancer Research UK. Cancer survival statistic. Available at: https://www.cancerresearchuk.org/health-professional/ cancer-statistics/survival (accessed 15.10.2020).https://www.cancerresearchuk.org/health-professional/
Cancer Research UK. Cancer survival statistic. Available at: https://www.cancerresearchuk.org/health-professional/ cancer-statistics/survival (accessed 15.10.2020).https://www.cancerresearchuk.org/health-professional/
Lyon A.R., Dent S., Stanway S. et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 2020;22(11):1945–60. DOI: 10.1002/ejhf.1920.
DOI: 10.1002/ejhf.1920